Ross Kedl, PhD

Professor of Immunology & Microbiology
University of Colorado

Ross KedlDr. Kedl received his PhD in 1997 in the Department of Laboratory Medicine and Pathology at the University of Minnesota in Minneapolis. Before joining the Faculty at the University of Colorado, Dr. Kedl was at 3M Pharmaceuticals working in their small molecule immune response modifier program. In his three years there, he spearheaded efforts at developing novel vaccine adjuvants, resulting in numerous publications and patents in the area of vaccine technology. Dr. Kedl returned to the academic sector in 2004 by joining the faculty in the Integrated Department of Immunology at the University of Colorado Health Sciences Center and National Jewish Medical Research Center where he continues to pursue the discovery and development of novel and clinically applicable vaccine technology. He is also the founder of a start-up pharmaceutical company, ImmuRx Inc., which focuses on developing therapeutic vaccines against chronic infectious diseases, such as HIV and cancer.

Biography from University of Colorado.

Contact

IDIGH Program
Research Institute of McGill University Health Centre
Glen site, Block E, Room EM3-3211
1001 Boul Décarie
Montreal, QC H4A 3J1

Program Manager

Eric Beliveau, Ph.D
eric.beliveau@mail.mcgill.ca
514-934-1934 ext 76170

Program Assistant

Joanne Krief
joanne.krief@mail.mcgill.ca
514-934-1934 ext 76174